oxybutynin

OXYBUTYNIN

Manufacturer: NCS HealthCare of KY, LLC dba Vangard Labs

Score: 141.0

Quick Summary

Oxybutynin is a muscarinic antagonist used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It works by relaxing the bladder muscle and increasing bladder capacity. The drug is available in extended-release tablets and should be taken whole with liquids, without chewing, dividing, or crushing. The recommended starting dose for adults is 5 mg or 10 mg once daily, and for pediatric patients aged 6 years and older, it is 5 mg once daily. Oxybutynin has several contraindications, including urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma. Common adverse reactions include dry mouth, constipation, diarrhea, headache, somnolence, and dizziness.

Key Clinical Findings and Indications

Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition

Important Safety Information

Warning

Oxybutynin can cause serious side effects, including urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma

Contraindications

Urinary retention
Gastric retention
Uncontrolled narrow-angle glaucoma
Known hypersensitivity to oxybutynin chloride or any component of oxybutynin chloride extended-release tablets

Adverse Reactions

Dry mouth
Constipation
Diarrhea
Headache
Somnolence
Dizziness

Dosing Recommendations

General Guidance

Dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability, up to a maximum of 30 mg/day for adults and 20 mg/day for pediatric patients

Overactive bladder

Adult Dose

5 mg or 10 mg once daily

Pediatric Dose

5 mg once daily for patients aged 6 years and older

Special Population Considerations

Pregnancy

There are no adequate data on oxybutynin chloride extended-release tablets use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

Nursing Mothers

Pediatric Use

Oxybutynin chloride extended-release tablets are not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing, or crushing, or in children under the age of 6